Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (483)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 715
1.

Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.

Autor(es): Dong, Jianghong; Chen, Shengwei; Li, Runfeng; Cui, Wei; Jiang, Haiming; Ling, Yixia; Yang, Zifeng; Hu, Wenhui
Fonte: Eur J Med Chem;108: 605-615, 2016 Jan 27.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26722757
Resumo: We previously reported potent hit compound 4 inhibiting the wild-type influenza A virus A/HK/68 (H3N2) and A/M2-S31N mutant viruses A/WS/33 (H1N1), with its latter activity quite weak. To further increase its potency, a structure-activity relationship study of a series of imidazole-linked pinanamine derivatives was conducted by modifying the imidazole ring of this compound. Several compounds of this series inhibited the amantadine-sensitive virus at low micromolar concentrations. Among them (mais)
2.

Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.

Autor(es): Silveira, Fernanda P; Abdel-Massih, Rima; Bogdanovich, Tatiana; Pakstis, Diana L; Routh, Rebecca L; Moss, Ronald B
Fonte: Antivir Ther;21(1): 71-4, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26133231
Resumo: We report a cystic fibrosis patient infected with influenza 2009H1N1 who had persistent viral shedding and clinical deterioration despite prolonged treatment with oseltamivir and zanamivir. The patient was diagnosed with H275Y neuraminidase inhibitor resistant influenza during treatment, thus was treated for 10 days with DAS181, an investigational host-directed inhaled sialidase fusion protein. Viral clearance occurred after 5 days of therapy and the patient became eligible for lung transpl (mais)
3.

Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.

Autor(es): Benedetti, E; Daniels, R S; Pontoriero, A; Russo, M; Avaro, M; Czech, A; Campos, A; Periolo, N; Gregory, V; McCauley, J W; Baumeister, E G
Fonte: Epidemiol Infect;144(4): 751-67, 2016 Mar.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26345289
Resumo: The activity and circulation of influenza viruses in Argentina was studied during 2012 as part of the Argentinean Surveillance for Influenza and other Respiratory Viruses, in the context of Global Influenza Surveillance. The antigenicity and molecular characteristics of haemagglutinins (HA) of circulating influenza A and B viruses were analysed to assess the emergence of virus variants. Susceptibility to oseltamivir and zanamivir was evaluated by enzymatic assay and results were backed-up b (mais)
4.

Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Autor(es): Ann, Julie; Abed, Yacine; Beaulieu, Edith; Bouhy, Xavier; Joly, Marie-Hélène; Dubé, Karen; Carbonneau, Julie; Hamelin, Marie-Eve; Mallett, Corey; Boivin, Guy
Fonte: Influenza Other Respir Viruses;10(2): 122-6, 2016 Mar.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26526406
Resumo: Viral fitness of a laninamivir-selected influenza A/Brisbane/10/2007-like (H3N2) isolate (LRVp9) containing a 237-amino acid neuraminidase deletion and a P194L hemagglutinin mutation was evaluated in vitro and in ferrets. LRVp9 and the wild-type (WT) virus showed comparable replication kinetics in MDCK-ST6GalI cells. Cultured virus was recovered between days 2 and 5 post-infection in nasal washes (NW) from the 4 WT-infected ferrets whereas no virus was recovered from the LRVp9-infected ani (mais)
5.

A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.

Autor(es): Jiang, Li; Liu, Ping; Bank, Claudia; Renzette, Nicholas; Prachanronarong, Kristina; Yilmaz, Lutfu S; Caffrey, Daniel R; Zeldovich, Konstantin B; Schiffer, Celia A; Kowalik, Timothy F; Jensen, Jeffrey D; Finberg, Robert W; Wang, Jennifer P; Bolon, Daniel N A
Fonte: J Mol Biol;428(3): 538-553, 2016 Feb 13.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26656922
Resumo: The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and (mais)
6.

Detection of Rare Drug Resistance Mutations by Digital PCR in a Human Influenza A Virus Model System and Clinical Samples.

Autor(es): Whale, Alexandra S; Bushell, Claire A; Grant, Paul R; Cowen, Simon; Gutierrez-Aguirre, Ion; O'Sullivan, Denise M; Zel, Jana; Milavec, Mojca; Foy, Carole A; Nastouli, Eleni; Garson, Jeremy A; Huggett, Jim F
Fonte: J Clin Microbiol;54(2): 392-400, 2016 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26659206
Resumo: Digital PCR (dPCR) is being increasingly used for the quantification of sequence variations, including single nucleotide polymorphisms (SNPs), due to its high accuracy and precision in comparison with techniques such as quantitative PCR (qPCR) and melt curve analysis. To develop and evaluate dPCR for SNP detection using DNA, RNA, and clinical samples, an influenza virus model of resistance to oseltamivir (Tamiflu) was used. First, this study was able to recognize and reduce off-target ampli (mais)
7.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Autor(es): Liang, Jiaming; Mesplède, Thibault; Oliveira, Maureen; Anstett, Kaitlin; Wainberg, Mark A
Fonte: J Virol;89(22): 11269-74, 2015 Nov.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26311878
Resumo: UNLABELLED: The R263K substitution in integrase has been selected in tissue culture with dolutegravir (DTG) and has been reported for several treatment-experienced individuals receiving DTG as part of salvage therapy. The R263K substitution seems to be incompatible with the presence of common resistance mutations associated with raltegravir (RAL), a different integrase strand transfer inhibitor (INSTI). T66I is a substitution that is common in individuals who have developed resistance again (mais)
8.

Influenza virusssurveillance by the instituto aolfo lutz, influenza season 20114: antiviral resistacee

Autor(es): Santos, Katia Corrêa de Oliveira; Silva, Daniela Bernardes Borges da; Benega, Margarete Aparecida; Paulino, Renato de Sousa; E Silva Jr, Elian Reis; Pereira, Dejanira dos Santos; Mussi, Aparecida Duarte Hg; Silva, Valéria Cristina da; V. Gubareva, Larissa; Paiva, Terezinha Maria de
Fonte: Rev. Inst. Med. Trop. Säo Paulo;57(1): 92-92, Jan-Feb/2015.
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 736371
9.

Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.

Autor(es): Piret, Jocelyne; Goyette, Nathalie; Eckenroth, Brian E; Drouot, Emilien; Götte, Matthias; Boivin, Guy
Fonte: J Virol;89(8): 4636-44, 2015 Apr.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25673718
Resumo: UNLABELLED: DNA polymerases of the Herpesviridae and bacteriophage RB69 belong to the α-like DNA polymerase family. In spite of similarities in structure and function, the RB69 enzyme is relatively resistant to foscarnet, requiring the mutation V478W in helix N to promote the closed conformation of the enzyme to make it susceptible to the antiviral. Here, we generated recombinant herpes simplex virus 1 (HSV-1) and human cytomegalovirus (HCMV) mutants harboring the revertant in UL30 (W7 (mais)
10.

The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.

Autor(es): Yamaya, Mutsuo; Nadine, Lusamba; Kubo, Hiroshi; Saito, Kousuke; Saito, Reiko; Nishimura, Hidekazu
Fonte: J Med Virol;87(1): 25-34, 2015 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24838828
Resumo: Defining the effects of neuraminidase inhibitors on influenza virus infection may provide important information for the treatment of patients. The effects of neuraminidase inhibitors have been examined using various methods, including viral release from kidney cells. However, the effects of neuraminidase inhibitors on viral release from primary cultures of human tracheal epithelial cells, which retain functions of the original tissues, have not been studied. The effects of neuraminidase inh (mais)
11.

Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.

Autor(es): Correia, Vanessa; Santos, Luis A; Gíria, Marta; Almeida-Santos, Maria M; Rebelo-de-Andrade, Helena
Fonte: J Med Virol;87(1): 45-56, 2015 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25042157
Resumo: Neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently the only effective antiviral drugs available worldwide for the management of influenza. The potential development of resistance is continually threatening their use, rationalizing and highlighting the need for a close and sustained evaluation of virus susceptibility. This study aimed to analyze and characterize the phenotypic and genotypic NAIs susceptibility profiles of A(H1N1)pdm09 viruses circulating in Portugal from (mais)
12.

Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Autor(es): Marjuki, Henju; Mishin, Vasiliy P; Chesnokov, Anton P; Jones, Joyce; De La Cruz, Juan A; Sleeman, Katrina; Tamura, Daisuke; Nguyen, Ha T; Wu, Ho-Sheng; Chang, Feng-Yee; Liu, Ming-Tsan; Fry, Alicia M; Cox, Nancy J; Villanueva, Julie M; Davis, Charles T; Gubareva, Larisa V
Fonte: J Infect Dis;211(2): 249-57, 2015 Jan 15.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 25124927
Resumo: BACKGROUND: Patients contracting influenza A(H7N9) infection often developed severe disease causing respiratory failure. Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but information on drug-resistance markers for influenza A(H7N9) is limited. METHODS: Four NA variants of A/Taiwan/1/2013(H7N9) virus containing a single substitution (NA-E119V, NA-I222K, NA-I222R, or NA-R292K) recovered from an oseltamivir-treated patient were tested for NAI susceptibility in vitr (mais)
Resultados  1-12 de 715